Notice of China Resources Shuanghe on convening the 6th Extraordinary General Meeting of Shareholders in 2024
Announcement of China Resources Shuanghe on the changes of directors, president and legal representative
China Resources Shuanghe\'s announcement on the progress of the 2024 “Improve Quality, Increase Efficiency, and Value Return” action plan
China Resources Shuanghe Company\'s “Articles of Association” (revised by the 4th meeting of the 10th board of directors on October 25, 2024)
Announcement of China Resources Shuanghe on changing the registered capital and amending the company\'s “Articles of Association”
Announcement of China Resources Shuanghe on the approval notice for sildenafil citrate tablets from its wholly-owned subsidiary China Resources Secco Pharmaceutical Co., Ltd.
China Resources Shuanghe: China Resources Shuanghe\'s Announcement on Changing the Secretary of the Board
Notice to creditors of China Resources Shuanghe\'s Notice to Creditors on Repurchase and Cancellation of Certain Restricted Shares to Reduce Registered Capital
The “Articles of Association” of China Resources Shuanghe Company (revised at the 2nd meeting of the 10th board of directors on August 21, 2024, and reviewed and approved by the 5th Extraordinary General Meeting of Shareholders in 2024 on September 19, 2024)
Legal Opinion of Beijing Zhonglun Law Firm on the 5th Extraordinary General Meeting of Shareholders of China Resources Shuanghe in 2024
Announcement of Resolutions of the Fifth Shareholders\' Meeting of China Resources Shuanghe 2024
Announcement of China Resources Shuanghe on the approval notice for the listing application of valproic acid and sodium valproate from the holding subsidiary Hunan Xiangzhong Pharmaceutical Co., Ltd.
Documents of the 5th Extraordinary General Meeting of Shareholders of China Resources Shuanghe 2024
Announcement of China Resources Shuanghe on the consistent evaluation of the quality and efficacy of generic drugs for injection of omeprazole sodium by its wholly-owned subsidiary Shuanghe Pharmaceutical (Hainan) Co., Ltd.
Announcement of China Resources Shuanghe on the fact that the wholly-owned subsidiary China Resources Zizhu Pharmaceutical Co., Ltd. obtained a notice of approval for drug clinical trials by ZP036
Notice of China Resources Shuanghe on Convening the Fifth Extraordinary General Meeting of Shareholders in 2024
China Resources Double-Crane Pharmaceutical Company's "Articles of Association" (Revised at the second meeting of the tenth Board of Directors on August 21, 2024)
China Resources Double-Crane Pharmaceutical Announcement on Changes in Registered Capital and Amendment of the Company's Articles of Association
China Resources Double-Crane Pharmaceutical "Board of Directors' Strategic Committee Working Procedures" (revised and approved at the second meeting of the tenth Board of Directors on August 21, 2024)
Announcement from China Resources Double-Crane Pharmaceutical Regarding Resignation of Supervisor.
No Data
No Data